Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...
Digital Photography Review on MSN7h
Fujifilm GFX100RF initial review: big sensor, bigger dreams
The GFX100RF occupies a new space in Fujifilm's lineup and comes with a new design. It's essentially the long-rumored 'medium ...
UK Dental Services Market to Reach USD 48.83 Billion with CAGR 19.4% | Trend, Growth, Forecast By 2032
The UK Dental Services Market benefits from MyDentist's USD 10.3 million investment, expanding access through four new ...
BioInvent International: BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma
LUND, SE / ACCESS Newswire / March 20, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class i ...
Autolus Therapeutics plc: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and ...